SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-063871
Filing Date
2022-05-23
Accepted
2022-05-23 16:30:21
Documents
12
Period of Report
2022-05-20
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2216631d1_8k.htm   iXBRL 8-K 32486
  Complete submission text file 0001104659-22-063871.txt   207969

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kprx-20220520.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kprx-20220520_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kprx-20220520_pre.xml EX-101.PRE 22605
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2216631d1_8k_htm.xml XML 3721
Mailing Address 1371 EAST 2100 SOUTH SUITE 200 SALT LAKE CITY UT 84105
Business Address 1371 EAST 2100 SOUTH SUITE 200 SALT LAKE CITY UT 84105 (781) 788-8869
KIORA PHARMACEUTICALS INC (Filer) CIK: 0001372514 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36672 | Film No.: 22952107
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences